1World Health Organization. " Hepatitis B fact sheet". Available at http://www, who. int/mediacentre/factsheets/fs204/en/. Accessed December 9, 2004.
2Asian Liver Foundation. " HBV: A silent killer. " Available at http://liver, stanford, edu/files/handbook, pdf. Accessed September 30, 2004.
3Hepatitis B Foundation. "Liver cancer". Available at http://www.hepb. org/PrinterFriendly, aspx? PagelD = 256&Locale = en-US.Accessed September 30, 2004.
4Gish RG, De Man RA, Pedersen C, et al. Sustained response offtreatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naǐve, HBeAg ( + ) patients: 24-week follow-up results of phase 3 study ETV-022 presented at 40th EASL 2005.
5Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg + chronic hepatitis B : results of phase Ⅲ study ETV-022 in nucleoside-naǐve patients.Hepatology, 2004, 40 : 193A.
6Shouval D, Lal CL, Lok A, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naǐve HBeAg- chronic hepatitis B: results of phase Ⅲ trial ETV-027.Hepatology, 2004, 40:728A.
7Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory,HBeAg + chronic hepatitis B : results of phaseⅢ study ETV-026.Hepatology, 2004, 40:664A.
8Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002, 123 : 1831-1838.
9Colonno RJ, Rose RE, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase Ⅱ & Ⅲ studies is only observed in lamivudine refractory patients. Poster 1146. Presented at 40th EASL 2004.
10Manns MP, Raptopoulou-Gigi M, Sollano J, et al. Entecavir is well-tolerated for the treatment of nucleoside-naǐve and lamivudine-refractory chronic hepatitis B viral infection: Phase Ⅱ/Ⅲ safety result. Abstract 511. Presented at 40th EASL 2005.
